Cell and Gene Therapy Catapult’s Post

How can international partnerships enhance haematology training both in the UK and in other countries? What do these partnerships looks like now and what might be direction of travel in the future? With a focus on West Africa our diverse panel of speakers share their experiences before we discuss these questions further in an interactive round table discussion. #BSH24 #ASM

i would like to share the link to 2 useful on line tools that may semplify the work of scientists working with recombinant monoclonal antibodies: 1) ABRSA ia simple and useful tool for antibody numberimg and cdr identification https://lnkd.in/d5jcgW6z 2) PLABDAB is a repository containing over 150,000 paired antibody sequences derived from patents and academic paper. it is vero usefull to underand if a mab sequence is patented or not. https://lnkd.in/daJfZ_K3 #mab #cdr #sequences #research #r&d

Good timing After the #RSC #RSB #RPS #QPSymposium to build on knowledge!

The IACME is seeking nominations for medicolegal professionals and ally awards! Nominations are due on April 30, 2024. Awards will be provided at the Membership Meeting during the IACME’s 2024 Training Symposium. More info here: https://lnkd.in/guSbD7aJ #medicolegal #coroner #medicalexaminer #MDI #deathinvestigator #medicolegaldeathinvestigator #award #nomination

Extension of the BPR Review Programme At the 100th meeting of the Biocide competent authorities (CA) in June 2023, it was decided to extend the extension of the review programme under the BPR (Regulation No. 528/2012) until December 31, 2030. Subsequent meetings in September and December 2023 discussed proposed actions for member states (MS) to ensure the successful completion of the RP within the new deadline. The European Commission is currently working on a proposal for a Delegated Regulation on this matter. Originally set to conclude by the end of 2024, the RP's extension became inevitable, given that only 47% of the programme has been completed. The EU's plan includes actions such as resource allocation in MS, governance in application assessments for approval, and additional measures to facilitate the review process. MS are urged to allocate adequate resources and review financing mechanisms to establish a full-recovery system if required. Additionally, specific actions to address backlog active substance reports from certain MS are required, mandating their conclusion by December 31, 2025, to ensure timely availability of corresponding BPC opinions. Concerning rules and procedures, an emphasis is placed on improved compliance, while new technical document guidance agreed after January 1, 2024 will not be applied to ongoing RP applications. Each MS is required to provide information to ECHA on the status of the endocrine disruption (ED) assessment for each active substance in the review programme, with a maximum deadline of December 31, 2026 to submit missing information. One of the more important actions outlined in the CA meeting reports is the encouragement for MS to prioritise finalising RP evaluations over active substance renewals, except for specific cases. This reprioritisation is suspected to impact ongoing renewals by introducing delays. Additionally, proposals for refining practices and managing applications have been set forth. By addressing key challenges and implementing these comprehensive actions, the EU aims to achieve its revised goal of concluding the review programme by December 2030. MS are invited to collaborate in implementing these actions, indicating a concerted effort towards a more sustainable and secure regulatory framework for biocides in the EU. For those interested in viewing the full report and comprehensive actions outlined, the CA reports are published on CIRCABC https://lnkd.in/d_QS_UHz If you need support with the authorisation or support of biocidal products across Europe, please do not hesitate to contact Kerona at [email protected] or call the office at +353 (0)1 849 5284.

👨⚕️💼 Tap into Expertise with MHN's Physicians Panel! 💊💡 Plan your project here: https://lnkd.in/er-_cxKu Attention pharmaceutical brands and healthcare innovators! 📣 Are you searching for a reliable platform to test and refine your new marketing strategies, medicines, and products? Look no further than MHN's esteemed Physicians Panel! Our panel comprises a diverse network of medical professionals from various specialties and backgrounds, offering unparalleled expertise and insights into the ever-evolving healthcare landscape. Whether you're launching a new medication, exploring innovative treatment options, or fine-tuning your marketing campaigns, our Physicians Panel provides a robust platform to gather valuable feedback and make informed decisions. With MHN, you can engage with leading physicians, clinicians, and healthcare experts who are at the forefront of medical advancements and patient care. Our panelists offer invaluable perspectives on efficacy, safety, and patient outcomes, helping you navigate regulatory requirements and market dynamics with confidence. Don't miss out on this opportunity to collaborate with top-tier healthcare professionals and leverage their expertise to drive innovation and success in your industry. Reach out to MHN today to learn more about how our Physicians Panel can help you test new marketing strategies, medicines, and products and stay ahead in the competitive healthcare market! #MHNInsights #PhysiciansPanel #HealthcareInnovation #Pharmaceuticals #MedicalExperts 💉  #RepresentativeSamples #MarketResearch 🚀🔍 #QualitativeResearch #QuantitativeResearch #MHN #MHNInsights

👨⚕️💼 Tap into Expertise with MHN's Physicians Panel! 💊💡 Plan your project here: https://lnkd.in/er-_cxKu Attention pharmaceutical brands and healthcare innovators! 📣 Are you searching for a reliable platform to test and refine your new marketing strategies, medicines, and products? Look no further than MHN's esteemed Physicians Panel! Our panel comprises a diverse network of medical professionals from various specialties and backgrounds, offering unparalleled expertise and insights into the ever-evolving healthcare landscape. Whether you're launching a new medication, exploring innovative treatment options, or fine-tuning your marketing campaigns, our Physicians Panel provides a robust platform to gather valuable feedback and make informed decisions. With MHN, you can engage with leading physicians, clinicians, and healthcare experts who are at the forefront of medical advancements and patient care. Our panelists offer invaluable perspectives on efficacy, safety, and patient outcomes, helping you navigate regulatory requirements and market dynamics with confidence. Don't miss out on this opportunity to collaborate with top-tier healthcare professionals and leverage their expertise to drive innovation and success in your industry. Reach out to MHN today to learn more about how our Physicians Panel can help you test new marketing strategies, medicines, and products and stay ahead in the competitive healthcare market! #MHNInsights #PhysiciansPanel #HealthcareInnovation #Pharmaceuticals #MedicalExperts 💉  #RepresentativeSamples #MarketResearch 🚀🔍 #QualitativeResearch #QuantitativeResearch #MHN #MHNInsights

👨⚕️💼 Tap into Expertise with MHN's Physicians Panel! 💊💡 Plan your project here: https://lnkd.in/er-_cxKu Attention pharmaceutical brands and healthcare innovators! 📣 Are you searching for a reliable platform to test and refine your new marketing strategies, medicines, and products? Look no further than MHN's esteemed Physicians Panel! Our panel comprises a diverse network of medical professionals from various specialties and backgrounds, offering unparalleled expertise and insights into the ever-evolving healthcare landscape. Whether you're launching a new medication, exploring innovative treatment options, or fine-tuning your marketing campaigns, our Physicians Panel provides a robust platform to gather valuable feedback and make informed decisions. With MHN, you can engage with leading physicians, clinicians, and healthcare experts who are at the forefront of medical advancements and patient care. Our panelists offer invaluable perspectives on efficacy, safety, and patient outcomes, helping you navigate regulatory requirements and market dynamics with confidence. Don't miss out on this opportunity to collaborate with top-tier healthcare professionals and leverage their expertise to drive innovation and success in your industry. Reach out to MHN today to learn more about how our Physicians Panel can help you test new marketing strategies, medicines, and products and stay ahead in the competitive healthcare market! #MHNInsights #PhysiciansPanel #HealthcareInnovation #Pharmaceuticals #MedicalExperts 💉  #RepresentativeSamples #MarketResearch 🚀🔍 #QualitativeResearch #QuantitativeResearch #MHN #MHNInsights

To accept modifications or not to accept modifications? That is the question.... At the 104th CA meeting, in June, the borders of the procedure for renewal of product authorization will be discussed. Will it be allowed to include changes to the product and its authorization during renewal process or will an additional procedure (modification) required after renewal? Stay tuned.... https://lnkd.in/dzX3T-CJ #biocides #authorization #BPR

🚀 Launch Alert! 🌟 The IRISS Community Platform on Safe and Sustainable-by-Design (SSbD) is now live! 🌱 This innovative platform aims to foster collaboration and share best practices in SSbD, bringing together industry, academia, policymakers, and more. 🤝 You can access the following services through this digital platform: ✴ Connect and discuss topics around SSbD. ✴ Join and engage in working groups related to value chains such as textiles, construction, automotive, electronics, energy, packaging, and fragrances. ✴ Find information and guidelines about SSbD for industry. The IRISS – International SSbD network seeks to connect, synergize, and transform the SSbD community both in Europe and globally, promoting a lifecycle approach. 🌍 As a partner in the IRISS project working closely with the value chains, Cefic supports this new platform and invites all interested actors in SSbD to join! 🌟 #IRISS #SSbD #Sustainability #Innovation #GreenTransition #Cefic #SafeDesign #SustainableFuture #Collaboration